← 返回

伴骨性或软骨样分化的黑色素瘤:8 例报告,包括 SATB2 表达和突变分析

英文原题:Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.

查看英文原题

Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.

PubMed 2021/06/02(内容时间) Pathology Q1 · IF 3.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

黑色素瘤可出现骨软骨分化,但关于这一罕见亚型的报道很少。本文报告 8 例伴骨软骨分化的黑色素瘤,介绍其临床、病理和分子特征。病例与性别(男性 5 例、女性 3 例)或年龄(23–84 岁)无关联。病例包括原发黑色素瘤 6 例和远处转移 2 例;多数起源于皮肤(7/8),另 1 例来自黏膜。TIL(肿瘤浸润淋巴细胞)评分为 0–3 分(中位数 1),2/8 个病灶有炎症改变或既往创伤证据。新一代测序未发现肿瘤中存在复发性突变;检测到的突变更符合黑色素瘤,而非骨肉瘤样病变。多数肿瘤表达黑色素瘤标志物,包括 S100、HMB45、Melan-A、SOX10 和 MITF。成骨细胞标志物 SATB2 的染色从阴性到广泛阳性不等。研究显示,伴骨软骨分化的黑色素瘤临床表现具有异质性,且癌症相关基因中没有特征性复发突变。若骨软骨病变诊断不确定,可通过检测 BRAF、NRAS、NF1 等典型黑色素瘤基因突变,以及 S100、HMB45、Melan-A、SOX10 和 MITF 免疫组化阳性,支持黑色素瘤诊断。此类病变可能 SATB2 阳性,因此不能以 SATB2 阳性排除黑色素瘤。

展开英文摘要原文

Melanoma can present with osteocartilaginous differentiation, however few reports exist on this rare subtype.

We present eight cases of melanoma with osteocartilaginous differentiation to highlight its clinical, pathological and molecular features. The cases showed no association with gender (5 males and 3 females) or age (range 23-84 years). Cases included both primary melanomas and distant metastases (6 and 2, respectively), with the majority arising from cutaneous sites (7/8) and the remaining case from a mucosal site.

Tumour-infiltrating lymphocyte (TIL) score ranged from 0 to 3 (median 1), and 2/8 lesions had evidence of inflammatory changes or antecedent trauma. No recurrent mutations were found in the tumours by next generation sequencing, and the mutations observed were typical of melanoma rather than osteosarcomatous lesions. The majority of tumours stained positive for melanoma markers including S100, HMB45, Melan-A, SOX10 and MITF. Staining of the osteoblastic marker SATB2 varied from negative to widespread positive.

We demonstrate that melanomas with osteocartilaginous differentiation are heterogeneous in presentation and are not typified by a recurrent mutation in cancer associated genes. Where uncertainty exists in diagnosing an osteocartilaginous lesion, a diagnosis of melanoma can be supported by the presence of genomic mutations typical of melanoma such as BRAF, NRAS and NF1, and IHC staining positive for S100, HMB45, Melan-A, SOX10 and MITF. SATB2 may be positive in these lesions and thus should not be used to rule out melanoma.

论文信息

作者
Gallagher SJ、Bailey T、Rawson RV、Mahar AM、Thompson JF、Long GV、Wilmott JS、Scolyer RA
第一作者单位
Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.Australia
通讯作者单位
Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; NSW Health Pathology, Sydney, NSW, Australia. Electronic address: richard.scolyer@health.nsw.gov.au.Australia
期刊
Pathology2021 Dec
原文标识
PubMed 34090666 · DOI 10.1016/j.pathol.2021.02.012